• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Sera Prognostics Inc.

    1/16/26 2:45:31 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Sera Prognostics, Inc.

    (Name of Issuer)


    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    81749D107

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81749D107


    1Names of Reporting Persons

    Whetstone Capital Advisors, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    KANSAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    3,459,713.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    3,459,713.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,459,713.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    81749D107


    1Names of Reporting Persons

    David Atterbury
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    3,459,713.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    3,459,713.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,459,713.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Sera Prognostics, Inc.
    (b)Address of issuer's principal executive offices:

    2749 East Parleys Way, Suite 200, Salt Lake City, Utah 84109
    Item 2. 
    (a)Name of person filing:

    Whetstone Capital Advisors, LLC ("WCA") and Mr. David Atterbury (collectively the "Reporting Persons").
    (b)Address or principal business office or, if none, residence:

    2001 Shawnee Mission Parkway, Shawnee Mission, Kansas 66205
    (c)Citizenship:

    United States of America
    (d)Title of class of securities:

    Class A Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    81749D107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,459,713
    (b)Percent of class:

    9.2%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:


     (ii) Shared power to vote or to direct the vote:

    3,459,713

     (iii) Sole power to dispose or to direct the disposition of:


     (iv) Shared power to dispose or to direct the disposition of:

    3,459,713

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Whetstone Capital Advisors, LLC
     
    Signature:/s/ David Atterbury
    Name/Title:Manager
    Date:01/16/2026
     
    David Atterbury
     
    Signature:/s/ David Atterbury
    Name/Title:David Atterbury
    Date:01/16/2026
    Get the next $SERA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    12/15/2025$5.00Buy
    Jefferies
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Information Officer Harrison Robert Gardner sold $6,000 worth of shares (2,000 units at $3.00), decreasing direct ownership by 2% to 84,788 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    12/30/25 6:41:19 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Executive Officer Lindgardt Zhenya sold $13,753 worth of shares (4,155 units at $3.31), decreasing direct ownership by 0.54% to 763,926 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    12/11/25 7:58:14 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Data Officer Kearney Paul sold $4,015 worth of shares (1,213 units at $3.31), decreasing direct ownership by 0.72% to 167,383 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    12/11/25 7:57:40 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Sera Prognostics Inc.

    SCHEDULE 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    1/16/26 2:45:31 PM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    1/8/26 5:20:58 PM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    1/7/26 9:12:23 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Sera Prognostics with a new price target

    Jefferies initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $5.00

    12/15/25 10:01:13 AM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics downgraded by Citigroup with a new price target

    Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

    3/30/22 7:52:32 AM ET
    $SERA
    Medical Specialities
    Health Care

    Oppenheimer initiated coverage on Sera Prognostics with a new price target

    Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

    11/19/21 4:55:47 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications

    Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions. SALT LAKE CITY, Jan. 7, 2026 /PRNewswire/ -- A randomized controlled trial of 5,018 women has found that a simple blood test, when paired with targeted interventions, can significantly reduce the risk of preterm birth and improve outcomes for newborns. The findings, published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine, highlight the effectiveness of the PreTRM Test in identifying women at higher risk for spontaneous preterm birth and guiding preventive care.

    1/7/26 8:30:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Announces Publication Acceptance for PRIME Study

    The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study were accepted for publication in a peer-reviewed  journal.

    11/24/25 8:00:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $SERA
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

    SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as a leader in women's health diagnostics to improve the health of pregnant women and newborns. Dr. Inglis joins Se

    10/1/25 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

    Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

    5/8/25 4:40:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Financials

    Live finance-specific insights

    View All

    SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an inaugural pilot in Nevada actively enrolling Medicaid patients, while engaging with multiple payers across thirteen states, collectively representing a significant

    11/13/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025

    SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report third quarter fiscal year 2025 financial results on Thursday November 13, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    10/30/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2025 ended June 30, 2025. Second Quarter and Recent Highlights: Ongoing progress in engaging Medicaid plans in targeted states with prior PreTRM clinical study experience. Notable traction in two particular states with above-average premature birth rates, presenting strong commercial o

    8/6/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/4/24 7:19:49 AM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Sera Prognostics Inc.

    SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    4/1/24 7:33:43 PM ET
    $SERA
    Medical Specialities
    Health Care